Alliance, HMR deal

HMR received exclusive manufacturing and worldwide marketing rights to ALLP's LiquiVent (perflubron), an oxygen-carrying liquid to treat acute respiratory distress syndrome (ARDS).

The total value of the deal could reach $90 million, which includes an undisclosed minority equity position in ALLP, in the range of 5-10 percent, a licensing fee, and milestones. ALLP had 24.8 million shares outstanding as of Sept. 30. ...